Estimation of the Percentage of US Patients With Cancer Who Are Eligible for Immune Checkpoint Inhibitor Drugs

This cross-sectional study estimates the percentage of US patients with cancer who are eligible for immune checkpoint inhibitor drugs.

Detalles Bibliográficos
Autores principales: Haslam, Alyson, Gill, Jennifer, Prasad, Vinay
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2020
Materias:
Research Letter
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7063495/
https://www.ncbi.nlm.nih.gov/pubmed/32150268
http://dx.doi.org/10.1001/jamanetworkopen.2020.0423
Descripción
Sumario:This cross-sectional study estimates the percentage of US patients with cancer who are eligible for immune checkpoint inhibitor drugs.

Ejemplares similares